Journal Scans
Palifermin Decreases Severe Oral Mucositis of Patients Undergoing Postoperative Radiochemotherapy for Head and Neck Cancer: A Randomized, Placebo-Controlled Trial
Palifermin Protective Against Mucositis in Postoperative CRT for Head and Neck Cancer
M Henke, M Alfonsi, P Foa, J Giralt, E Bardet, L Cerezo, M Salzwimmer, R Lizambri, L Emmerson, MG Chen, D Berger
20110513
2011 Jun 13
J Clin Oncol
Palifermin Decreases Severe Oral Mucositis of Patients Undergoing Postoperative Radiochemotherapy for Head and Neck Cancer: A Randomized, Placebo-Controlled Trial
J Clin Oncol. 2011 Jun 13;[Epub Ahead of Print], M Henke, M Alfonsi, P Foa, J Giralt, E Bardet, L Cerezo, M Salzwimmer, R Lizambri, L Emmerson, MG Chen, D Berger
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Combined chemoradiotherapy (CRT) offers improved outcomes after resection of locally advanced head and neck cancer but also increases the risk of oral mucositis, a debilitating and potentially dose-limiting toxicity of locoregional treatment. Palifermin, an analogue of keratinocyte growth factor, is FDA approved to prevent and treat mucositis in patients undergoing high-dose myelotoxic therapy for hematologic malignancies. In this multicenter, randomized, placebo-controlled trial, Henke et al evaluated...
